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Abstract
Background:  Thyroid  cancer  is  the  most  common  malignancy  of  the  endocrine  system,  the  papil-
lary variant  accounts  for  80--90%  of  all  diagnosed  cases.  In  the  development  of  papillary  thyroid
cancer, BRAF  and  RAS  genes  are  mainly  affected,  resulting  in  a  modiﬁcation  of  the  system
of intracellular  signalling  proteins  known  as  ‘‘protein  kinase  mitogen-activated’’  (MAPK)  which
consist of  ‘‘modules’’  of  internal  signalling  proteins  (Receptor/Ras/Raf/MEK/ERK)  from  the  cell
membrane  to  the  nucleus.  In  thyroid  cancer,  these  signanling  proteins  regulate  diverse  cellular
processes such  as  differentiation,  growth,  development  and  apoptosis.  MAPK  play  an  impor-
tant role  in  the  pathogenesis  of  thyroid  cancer  as  they  are  used  as  molecular  biomarkers  for
diagnostic, prognostic  and  as  possible  therapeutic  molecular  targets.  Mutations  in  BRAF  gene
have been  correlated  with  poor  response  to  treatment  with  traditional  chemotherapy  and  as
an indicator  of  poor  prognosis.
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Objective:  To  review  the  molecular  mechanisms  involved  in  intracellular  signalling  of  BRAF  and
RAS genes  in  thyroid  cancer.
Conclusions:  Molecular  therapy  research  is  in  progress  for  this  type  of  cancer  as  new  molecules
have been  developed  in  order  to  inhibit  any  of  the  components  of  the  signalling  pathway
(RET/PTC)/Ras/Raf/MEK/ERK;  with  special  emphasis  on  the  (RET/PTC)/Ras/Raf  section,  which
is a  major  effector  of  ERK  pathway.
© 2016  Academia  Mexicana  de  Cirug´ıa  A.C.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE
Cáncer  de  tiroides;
Cinasas  de  proteínas
activadas  por
mitógenos  MAPK;
Mutaciones  BRAF
Mecanismos  de  sen˜alización  intracelular  en  cáncer  de  tiroides
Resumen
Antecedentes:  El  cáncer  de  tiroides  es  el  tumour  maligno  más  frecuente  del  sistema  endocrino;
la variante  papilar  representa  entre  el  80  y  el  90%  de  todos  los  casos  diagnosticados.  En  el
desarrollo  del  cáncer  papilar  de  tiroides  están  afectados  principalmente  2  genes  llamados  BRAF
y RAS,  que  alteran  el  sistema  de  sen˜alización  intracelular  de  las  proteínas  conocidas  como
«cinasas de  proteínas  activadas  por  mitógenos» (MAPK,  por  sus  siglas  en  inglés  para  mitogen-
activated  protein  kinase)  y  que  se  componen  de  «módulos» de  proteínas  de  sen˜alización  interna
(Receptor/Ras/Raf/MEK/ERK),  que  van  de  la  membrana  celular  al  núcleo  y  que  en  el  cáncer  de
tiroides regulan  diversos  procesos  celulares,  como  la  diferenciación,  crecimiento,  desarrollo
y apoptosis.  Tienen  un  papel  importante  en  la  patogénesis  del  cáncer  de  tiroides,  debido  a
que son  usados  como  biomarcadores  moleculares,  como  elementos  de  diagnóstico,  pronóstico
y como  posibles  blancos  terapéuticos  moleculares.
Objetivo:  Revisar  los  mecanismos  moleculares  que  intervienen  en  las  vías  de  sen˜alización,  en
las que  están  involucradas  las  proteínas  de  los  genes  BRAF  y  RAS,  en  el  cáncer  de  tiroides.
Conclusiones:  Las  mutaciones  en  el  gen  BRAF  han  sido  correlacionadas  con  una  pobre  respuesta
al tratamiento  con  quimioterapia  tradicional,  además  de  ser  un  índice  de  mal  pronóstico.
La terapia  molecular  es  de  gran  interés  en  este  tipo  de  cáncer,  ya  que  se  han  desarrollado
medicamentos  que  actúan  inhibiendo  alguno  de  los  componentes  de  la  vía  de  sen˜alización
(RET/PTC)/Ras/Raf/MEK/ERK,  con  especial  énfasis  en  la  sección  (RET/PTC)/Ras/Raf,  que  con-
stituye un  efector  principal  de  la  vía  ERK.
© 2016  Academia  Mexicana  de  Cirug´ıa  A.C.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Thyroid  cancer  is  the  most  common  malignancy  of  the
endocrine  system,  and  represents  approximately  1%  of
cancer  cases  diagnosed  worldwide.  Differentiated  thyroid
cancer  includes  papillary  and  follicular  types.  The  most
frequent  is  papillary  carcinoma,  which  accounts  for  approx-
imately  80--90%  of  all  cases  diagnosed  and  most  frequently
presents  in  women  rather  than  men,  at  a  2:1  ratio.  Its
incidence  worldwide  has  signiﬁcantly  increased  during  the
last  3  decades,  probably  due  to  more  advanced  systems  of
diagnosis,  which  has  resulted  in  more  timely  diagnoses  and
increasingly  more  targeted  treatments.1--5 Recent  reports
indicate  that  there  is  a  similar  prevalence  in  diagnostic  ages,
regardless  of  ethnic  group.  However,  there  are  differences
in  prevalence  by  gender  and  ethnicity.  It  has  been  reported
that  Caucasian  men  and  women  present  a  prevalence  of  6.3%
and  7.1%;  in  the  English  population  prevalence  is  reported
c
c
at  4.3%  and  8.4%;  Hispanic  at  4.2%  and  6.7%  and  Asian  at
.4%  and  6.4%,  respectively.6 It  is  believed  that  genetic  fac-
ors,  environmental  inﬂuences  and  access  to  health  services
ay  be  factors  which  determine  the  incidence  of  thyroid
ancer  in  any  one  particular  region.  However,  during  the
ast  decade  a  sustained  increase  in  the  rate  of  thyroid  can-
er  worldwide  has  been  observed,  mainly  of  the  papillary
ype.6
3195  cases  of  thyroid  cancer  were  reported  in  Mexico
n  2008  (1351  male  and  1844  female),  which  represented
.5%  of  total  malignancies,  with  an  incidence  of  3  out  of
very  100,000  inhabitants  and  a  mortality  of  0.6  per  100,000
nhabitants,  becoming  the  sixth  causes  of  death  in  women
nd  the  thirteenth  cause  of  death  in  men,  and  with  maxi-
um  frequency  of  between  41  and  50  years  of  age:  60%  of
ases  occur  between  31  and  60.  With  regards  to  thyroid  can-
ers,  papillary  carcinoma  and  its  variants  represent  80.3%
nd  follicular  cancer  and  its  variants,  2.4%.7--9
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On  a  molecular  level,  papillary  thyroid  cancer  fre-
uently  presents  with  metabolic  changes  in  the  intracellular
ignalling  systems,  which  involve  the  activation  of  proteins
nown  as  mitogen-activated  protein  kinase  (MAPK).  The  lat-
er  have,  in  recent  years,  been  the  purpose  of  many  studies
ue  to  their  role  in  the  pathogenesis  of  thyroid  cancer  and
heir  use  as  molecular  biomarkers,  in  addition  to  their  poten-
ial  usage  for  diagnostic,  prognostic  purposes  and  as  possible
herapeutic  molecular  targets.10--12
enetic  changes  in  cancer
t  is  a  known  fact  that  changes  in  3  types  of  genes  may  be
esponsible  for  the  start  and  continuation  of  the  cancer:
a)  oncogenes,  (b)  tumour  suppressor  genes  and  (c)  stability
enes.  It  is  also  well  known  that  the  cell  has  several  mecha-
isms  to  safeguard  and  protect  the  organism  from  a  lethal,
otentially  carcinogenic  effect  such  as  a  genetic  mutation
nd  it  is  therefore  only  when  there  are  changes  in  several
enes  that  cancer  may  develop.12--14
A  mutation  in  an  oncogene  leads  to  a  gene  which  should
emain  constituitively  active  or  inactive  normally  becoming
nactive  or  active.  The  activation  of  an  oncogene  may  be
ue  to:  chromosomal  translocation,  abnormal  gene  ampliﬁ-
ation  or  intragenic  mutation  which  affects  a  vital  residual
xpression  for  the  activity  of  this  gene.  A  mutation  of  an
ncogene  allele  generally  sufﬁces  to  confer  lack  of  con-
rol  in  cellular  growth.  For  their  part,  tumour  suppressor
enes  act  against  what  may  be  a  genetic  mutation;  in  their
ase,  they  reduce  the  gene’s  activity  and  its  product.  This
nactivation  is  a  product  of  the  mutations  which  lead  to
he  loss  of  essential  residual  expressions  for  the  activity
f  a  protein  coded  by  this  gene,  which  in  turn  results  in
runcated  proteins,  albeit  due  to  deletion,  insertion  or  epi-
enetic  alterations.  The  third  type  of  cancer  genes  are
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igure  1  Table  illustrating  some  of  the  pathological  characteristic
ody.
ource:  adapted  from  Hanahan  and  Weinberg.18P.  Mondragón-Terán  et  al.
alled  stability  genes  or  ‘‘watchdog’’  genes.  In  their  case,
his  type  of  genes  promote  tumour  genesis  via  different
outes  to  the  other  2  types  of  tumour  genes  mentioned
reviously.  This  type  of  ‘‘watchdog’’  genes  are  the  ones
hich  are  mainly  engaged  in  repairing  all  changes  resul-
ing  from  DNA  replication  when  this  occurs  normally  or  is
xposed  to  a  mutagen.  Other  stability  genes  also  control  the
rocesses  which  involve  large  quantities  of  chromosomes,
uch  as  those  which  regulate  chromosomal  recombination
nd  segregation  which  occur  during  mitosis.  The  stabilis-
ng  genes  maintain  genetic  alterations  to  a  minimum,  and
hen  they  are  inactive,  there  is  an  increase  in  the  rate  of
utations.14--17
All  the  previously  described  mutations  function  in  the
ame  manner  as  a  normal  cellular  physiological  process.
ancer  cell  growth  may  be  provoked  by  the  activation  of
ncogenes,  which  control  the  cellular  cycle  on  inhibiting  cel-
ular  death  (apoptosis)  or  increasing  the  transition  of  cells
f  the  G0  to  G1  stage  (‘‘release  of  cell  arrest’’)  or  helping
o  supply  nutrients  when  phenomena  such  as  angiogenesis
ncrease.  It  is  important  to  remember  that  a mutation  is
eﬁned  as  any  change  in  the  sequence  of  the  genome  and
hat  these  changes  include  those  which  inﬂuence  a  pair  of
ases,  and  those  which  are  minor  or  major  changes  such
s:  deletions,  insertions,  ampliﬁcations  or  translocations.  All
ypes  of  mutations  may  present  in  cancer  cells  but  they  are
onsidered  to  be  a  disease  when  occurrence  of  a  mutation
osterior  to  development  is  pathogenic.14--17 Furthermore,
nce  the  cell  has  become  cancerous,  it  presents  with  a  series
f  metabolic,  molecular  and  structural  changes  which  allow
t  to  survive,  develop  and  even  metastasise.  Among  these
eneral  changes  may  be  found:  self-sufﬁciency  in  growth
actors,  lack  of  sensitivity  of  inhibiting  growth  factors,  a
apacity  for  invasion  into  nearby  tissues  and  metastasis,  a
otential  for  unlimited  replication,  an  increase  in  angio-
enesis  and  the  development  of  mechanisms  of  apoptosis
itivity to growth 
ibiting factors
Self sufficiency in 
growth factors
Increase in 
angiogenesis
Avoidance 
f apoptosis
s  acquired  by  a  cancer  cell  which  has  helped  it  to  survive  in  the
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Figure  2  (A)  Table  showing  an  intracellular  signalling  cas-
cade activated  by  a  membrane  receptor  which  activates  a
series of  kinases  downstream  grouped  one  after  the  other  in
a MAPKKK-MAPKK-MAPK  sequence  and  terminates  in  the  acti-
vation of  a  transcription  factor  which  originates  a  cellular
response.  (B)  Outline  of  the  activation  of  ERK-1/2  transcription
factor  through  the  intracellular  signalling  of  kinases  in  thyroid
cancer.  Initial  activation  through  a  tyrosincinase  (RET/PTC)  type
membrane  receptor  and  which  continues  downstream  through
t
s
1
k
i
g
i
u
f
w
a
r
k
R
i
M
n
s
s
t
e
t
w
p
I
rIntracellular  signalling  mechanisms  in  thyroid  cancer  
evasion  (Fig.  1).18 The  Knudson  hypothesis  has  considerably
contributed  to  the  understanding  of  how  mutations  in  genes
involved  in  the  development  of  cancer  work,  where  there
is  a  dominant  autosomic  heritage,  due  to  the  loss  of  func-
tion  of  a  tumour  suppressor  gene,  leading  to  the  subsequent
tissue-speciﬁc  mutation.  However,  these  contributions  were
prior  to  the  increasing  knowledge  we  now  have  regarding  the
regulation  of  the  non  coding  micro-RNA  and  RNA  which  has
led  to  the  ‘‘continuous  model  ‘‘of  tumour  suppressor  gene
regulation  where  not  only  hereditary  genetic  and  somatic
mutations  contribute  to  the  development  of  cancer,  but
also  the  epigenetic  elements,  such  as  the  microRNA  ele-
ments  which  signiﬁcantly  contribute  to  the  development  of
cancer.19
Molecular  systems  of  regularisation  and
intracellular  signalling
In  thyroid  cancer  there  are  a  number  of  genetic  alterations
which  are  related  to  cellular  progression  and  differenti-
ation.  These  alterations  may  be  summarised  in  2  main
categories:  (1)  chromosomal  rearranging  and  (2)  speciﬁc
mutation.  Both  alterations  primarily  inﬂuence  2  genes  called
BRAF  and  RAS.  The  mutations  of  several  of  these  2  genes
have  been  found  in  over  80%  of  cases  with  papillary  thy-
roid  cancer  and  rarely  overlap  in  the  same  tumour.  These
mutations  change  the  transduction  system  of  intracellu-
lar  signalling,  which  regulates  several  metabolic  pathways,
and  this  has  direct  repercussions  on  cellular  processes  such
as  differentiation,  expansion  and  apoptosis,  among  others.
In  accordance  with  current  data,  mutations  which  affect
BRAF  exclusively  exist  in  papillary  thyroid  cancer  and  in
anaplasic  thyroid  cancer,  but  have  not  been  reported  in
other  histological  types  of  thyroid  cancer,  such  as  follicular
thyroid  cancer  and  medullary  thyroid  cancer.  Further-
more,  it  has  been  reported  that  the  BRAFV600E  mutation
(replacement  of  a  valine  by  a  glutamic  acid  in  position
number  600)  is  found  in  almost  60%  of  all  types  of  thyroid
cancers.  The  mutations  lead  to  activation  in  the  MAP-kinase-
dependent  signalling  pathways  which  it  is  believed  are  an
early  event  in  the  development  and  progression  of  thyroid
cancer.20,21
The  cascade  of  MAP-kinase-dependent  signalling  pathway
processes  is  very  important,  since  these  processes  regulate
the  number  and  participation  of  genes  involved  in  prolifer-
ation,  differentiation  and  survival  of  cancer  cells.  The  MAP
kinase  system  is  composed  of  protein  signalling  ‘‘modules’’,
which  extend  from  the  cell  membrane  to  the  nucleus
and  which  are  preserved  from  yeasts  to  vertebrates.22--24
This  system  is  regulated  by  a  cascade  of  phosphorylations
where  other  phosphorylases  intervene,  located  in  2  places
in  relation  to  the  MAP  kinase:  (1)  ‘‘Upstream’’  and  (2)
‘‘downstream’’.20--25
The  centre  of  activation  of  any  metabolic  signal  linked
through  a  cascade  to  activate  a  MAP  kinase  pathway
upstream  is  composed  of  3  levels  of  kinases,  which  are
activated  in  a  sequence  through  the  activation  signal  of  a
membrane  receptor  with  tyrosine  kinase  activity  (Fig.  2A).
In  eukaryotes  cells  there  are  several  MAP  kinase-dependent
signalling  pathways,  which  are  activated  by  different  mech-
anisms  of  stimulae.  At  least  4  different  types  of  MAP  kinases
I
r
l
ohe sequence  of  the  Ras/B-Raf/MEK-1/2  kinases.
ubfamilies  have  been  identiﬁed  to  date  which  are:  ERK-
/2,  JNK-1/2/3,  P38-a/b/g/d  and  ERK-5.  The  ERK-1/2  MAP
inase  signalling  pathway  is  of  signiﬁcance  in  medicine  and
n  particular  for  a  better  understanding  of  the  molecular
eneration  and  regulation  mechanisms  of  thyroid  cancer.  It
s  primarily  activated  as  a  response  to  a  mitogentic  stim-
lus,  such  as  the  activation  of  a  receptor  for  a  growth
actor  (Fig.  2B).  The  ERK-1/2  MAP  kinase  signalling  path-
ay  is  initially  activated  upstream  with  the  activation  of
 membrane  receptor  to  which  a  ligand  has  bound.  The
eceptor  now  activates  a  G  type  protein  called  Ras  (with
inase  activity),  which  ‘‘recruits’’  a  MAPKKK  family  called
af  through  the  use  of  subsequent  phosphorylations  which,
n  turn,  activates  a  series  of  MAPKK  called  MEK-1/2.  Finally,
EK-1/2  activates  ERK-1/2which  is  translocated  inside  the
ucleus,  where  it  phosphorylates  transcription  factors  of
everal  genes,  producing  the  regulation  of  its  expres-
ion.  This  nuclear  translocation  is  required  in  response
o  stimulae  such  as  growth  factors,  which  regulate  the
ntry  into  the  cellular  cycle  or  the  cellular  differentia-
ion.  This  is  why  it  is  important  in  the  study  of  cancer,
hich  involves  the  before-mentioned  uncontrolled  cellular
rocesses.14,26--28
ntracellular  signalling  pathway:  Ras/Raf/MEK/ERK
eceptor  in  thyroid  cancert  has  been  considered  that  the  tumorigenesis  process
equires  the  presence  of  a  deregulation  of  the  intracel-
ular  signalling  processes,  which  involve  different  levels
f  MAP  kinases  cascades,  where  the  cancer  cells  acquire
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c38  
ifferent  capacities  such  as:  (1)  ignoring  signals  to  prolif-
rate;  (2)  avoiding  apoptosis;  (3)  becoming  insensitive  to
ntiproliferation  signals;  (4)  acquiring  an  unlimited  poten-
ial  to  replicate;  (5)  invading  and  producing  metastasis  to
ther  tissues  and  (6)  producing  angioigenesis,  which  pro-
ides  them  with  nutrients  and  vital  support.18,29
It  has  been  reported  that  different  malignancies  show
p  as  an  alteration  in  the  intracellular  signalling  path-
ay,  comprising  of  the  cascade  of  activation  in  sequence
f  the  Ras/Raf/MEK/ERK  kinases,  in  which  the  last  cas-
ade  effector  (which  is  the  ERK-kinase  protein)  is  activated
pstream  by  genetic  mutations  which  may  affect  the  dif-
erent  kinasees  located  in  some  of  the  levels  of  the  chain
eactions,  starting  with  an  over-expression  of  the  tyrosine
inase  type  receptor  and  most  frequently  with  mutations  in
he  Ras  and  Raf  proteins.  The  intracellular  signalling  cascade
n  a  cancer  cell  begins  with  the  activation  of  a  membrane
eceptor  (with  tyrosine  kinase  activity)  when  the  latter  binds
ith  its  ligand  or  through  an  external  stimulus  (e.g.  change
n  osmosis,  oxidative  stress,  lack  of  nutrients,  etc.).  Once
he  receptor  has  been  activated,  it  recruits  the  ﬁrst  effec-
or,  by  means  of  speciﬁc  phyosphylations,  of  a  signalling
ascade  which  is  a  MAPKKK  which  may  be  A-Raf,  B-Raf  or
af-1.  These  kinases  phosphylate  to  the  following  MAPKK
hich  are  MEK-1/2  and  ﬁnally  phosphylate  to  a  MAPK,  which
s  ERK-1  or  ERK-2,  which  are  in  turn  translocated  to  the
ucleus  to  initiate  activation/inhibition  of  speciﬁc  genes.
f  this  signalling  cascade  is  found  constitutively  in  all  normal
ells  of  the  body,  in  the  cancer  cell  each  component  of  the
hain  may  have  mutations  which  provoke  excessive  down-
tream  activation  of  their  kinase,  and  this  increases  cellular
ctivity  exponentially  through  the  activation/inhibition  of
peciﬁc  genes.  It  has  therefore  been  reported,  for  exam-
le,  that  the  mutations  in  the  Ras  and  Raf  kinases  (which
re  the  components  of  the  intracellular  pathway  composed
y  the  Ras/Raf/MEK/ERK  receptor),  are  found  in  all  types
f  thyroid  cancer,  primarily  in  papillary  thyroid  cancer.  This
ndicates  that  a  single  alteration  in  these  molecules  may  be
nough  to  lead  to  a  malignant  transformation  of  the  thyroid
ells.
It  is  thus  known  that  the  presence  of  the  mutation  called
RAFV600E  (consistent  in  the  presence  of  a  valine  residual,
nstead  of  a  glutamic  acid  residual,  in  position  600  of  the
-Raf  protein  kinase),  the  prevalence  of  which  has  been
eported  between  27%  and  80%  in  different  patient  groups
ith  thyroid  cancer,  leads  to  an  increase  of  over  400  times
n  the  activity  of  B-Raf,  which  produces  an  increase  in  the
ownstream  activity  of  the  ERk  effectors,  which  increase
heir  phosphorylant  capacity  and  therefore  the  activity  of
iverse  key  genes30 for  cellular  metabolism,  proliferation
nd  apoptosis.
The  most  frequently  reported  mutations  in  papillary  thy-
oid  cancer  are:  re-arrangements  in  the  RET/PTC  gene
membrane  receptor  with  tyrosine  kinase  activity)  and  B-
af  and  Ras  mutations  (proteins  with  kinase  activity).  They
re  all  involved  in  the  intracellular  signalling  pathway  which
ctivates  the  nuclear  ERK  effector.  These  alterations  are
xclusively  found  in  patients  with  papillary  thyroid  cancer,
hich  proves  that  every  separate  alteration  may  be  sufﬁ-
ient  to  lead  to  a  malignant  transformation  of  thyroid  cells.
he  proto-oncogene  called  RET  (rearranged  during  trans-
ection),  encodes  for  a  membrane  receptor  with  tyrosine
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inase  activity,  which  is  expressed  in  a  particular  man-
er  in  type  C  parafollicuar  cells  in  thyroid  cancer,  which
esults  in  aberrant  proteins  with  different  chimeric  forms
rom  the  receptor.  However,  their  expression  is  very  low
n  the  follicular  cells.  The  name  RET/PTC  (rearranged  dur-
ng  transfection/papillar  tyroid  cancer  associate)  has  been
iven  to  these  chimeric  forms.  To  date,  more  than  11  differ-
nt  types  of  RET/PTC  proteins  have  been  described,  where
ET/PTC1  and  RET/PTC3  are  the  most  frequently  found  in
hyroid  cancer.31,32
In  the  cancer  cell,  RET/PTC  leads  to  constituitive  down-
tream  activation  of  a  kinase  called  Ras.  It  is  now  known
hat  Ras  activates  a  large  number  of  molecules  which  act  as
ownstream  intracellular  signalling  systems  and  induce  can-
er  cell  invasion  properties.  It  has  been  reported  that  Ras
lso  activates  reactive  proteins  to  stress,  such  as  Raf  kinase,
hich  is  the  key  downstream  cytosolic  Ras  effector.
Several  isoforms  of  Raf  have  been  reported:  A-Raf,  B-
af  and  Raf-1  (also  called  C-Raf).  Raf  activation  includes
 series  of  highly  regulated  metabolic  steps,  which  start
ith  their  recruitment  of  the  internal  cellular  membrane
y  the  Ras  protein.  Once  Raf  has  been  activated  it  may
ind  downstream  with  other  kinases,  among  which  are  MEK-
 and  MEK-2.  For  activation,  as  well  as  Ras  being  activated,
he  Raf  isoforms  require  that  an  enzyme  with  protein  phos-
hatise  activity  known  as  Src-kinase  be  activated.  This
rotein  phosphorylates  or  dephosphorylates  certain  amino
cid  residues,  located  within  the  Raf  areas,  which  regulate
ts  inactive/active  state.  Of  the  3  known  isoforms  for  Raf,
soform  B-Raf  is  the  one  which  presents  with  the  highest
asal  level  activity  compared  with  A-Raf  or  Raf-1.  This  is
ery  signiﬁcant,  since  in  thyroid  cancer  a  large  number  of
utations  in  protein  B-Raf  have  been  reported,  compared
o  that  of  A-Raf  or  Raf-1.  This  has  led  to  the  use  of  B-Raf
s  a  tumour  marker  for  several  types  of  cancer,  and  specif-
cally  thyroid  cancer.  Moreover,  B-Raf  is  the  most  powerful
ownstream  activator  of  MEK-1  kinase,  which  is  the  ERK
ffector.
The  MEK-1  protein  is  a  protein  kinase  with  dual  activ-
ty,  since  it  is  able  to  phosphorylate  serine  and  tyrosine
esidues.  Once  MEK-1  has  been  activated  by  B-Raf,  the
ownstream  activation  of  the  ERK  effector  occurs,  which
s  a  serine/threonine  kinase  which  phosphorylates  diverse
roteins,  both  cytosolic  and  nuclear.  In  this  way,  the
yperactivation  of  the  signalling  cascade  which  regulates
RK  may  lead  to  the  arrest  of  the  cellular  cycle.  How-
ver,  if  there  is  an  aberration  in  any  of  the  sequences
f  the  signalling  cascade,  a  tumour  transformation  of  the
ell  may  be  induced.  The  response  kinetics  and  their
xtension  to  diverse  ligands  or  extracellular  stimulae  may
nduce  the  ERK  to  regulate  speciﬁc  diverse  biological  pro-
rammes  such  as  cellular  differentiation  and  proliferation
r  apoptosis.32
ntracellular  PI3K/Akt/mTOR  signalling  in  thyroid
ancern  addition  to  the  above  mentioned  intracellular  signalling,
here  is  also  the  phosphatidylinositol  -3  kinase/protein  B
Atk)  pathway/mammalian  target,  for  rapamicin  (mTOR),
lso  expressed  as  PI3K/Akt/mTOR.  This  signalling  pathway
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is  involved  in  process  such  as:  cellular  differentiation  and
growth,  progression  of  cellular  cycle,  endocitosis,  motility,
apoptosis  and  intermediate  metabolism  (related  primarily  to
glucose  uptake).33--35 In  the  last  few  years,  alterations  in  the
said  pathway  have  been  reported  in  several  types  of  cancer
such  as  thyroid,  gastric,  neuro-endocrine  and  ovarian.  Fur-
thermore,  it  has  been  observed  that  the  activation  of  this
pathway  in  cancer  cells  may  increase  resistance  to  cisplatin,
cabo-platin  and  paclitaxel  treatment,  and  as  a  result  their
study  may  help  to  understand  the  mechanisms  of  genesis  and
progression  of  the  cancer,  in  addition  to  the  mechanisms  of
tumour  resistance  for  being  a  possible  target,  for  molecular
therapy  and  the  management  of  thyroid  cancer.33--37
Phosphatidylinositol-3  kinase  (PI3K)  phosphorylates
groups  3-OH  of  the  inositol  ring  of  phosphatidylinositol
groups.  The  sub-products  of  the  reaction  of  PI3K  measure
the  reversible  nature  of  the  cytoplasm  membrane  location
of  proteins,  which  contain  complex  lipid  binding  commands
and  an  above  standard  increase  in  their  activity  associated
with  an  oncogenic  cellular  transformation.36,37
In  terms  of  intracellular  signalling  the  class  I  PI3K  may
be  a  downstream  effector  of  either  a  membrane  recep-
tor  with  tyrosincinase  activity  or  a  G  protein  attached  to
a  receptor.37,38 However,  the  protein  known  as  Akt  has  an
approximate  molecular  weight  of  57  kDa,  which  is  a  ser-
ine/threonine  kinase  that  belongs  to  the  kinase  family  where
they  following  may  be  found:  protein  kinase  A,  protein
kinase  G  and  protein  kinase  C.  The  Akt  is  also  known  as
protein  kinase  B  (PKB).37--41
The  protein  called  mTOR  is  a  kinase  serine/threonine
coded  by  the  FRAP  1  gene  and  is  the  primary  downstream
effector  of  the  complex  PI3K/Akt.  There  are  2  different
isoforms  of  mTOR,  called  mTORC1  and  mTORC2.  Each  one
is  a  protein  multicomplex  formed  by  several  components,
where  the  centre  is  the  protein  mTOR  itself,  to  which  sev-
eral  sub-units  have  been  added.  The  complex  mTORC1  is
formed  by  the  protein  mTOR  associated  with  the  protein
RAPTOR,  which  works  as  a  link  and  positively  regulates
mTOR.  It  is  also  associated  with  2  negative  regulators  which
are  PRAS40  and  the  protein  DEPTOR,  whilst  the  sub-unit
mLST8,  combined  with  the  complex  mTORC1,  regulates
its  activity.39--42 The  intracellular  communication  pathway
measured  by  mTORC1  is  involved  in  cellular  growth  and
differentiation  whilst  the  complex  mTORC2  confers  insen-
sitivity  to  rapamicine.41,42 De-regulation  of  mTOR  activity
is  correlated  with  the  presence  of  hamartomas,  tuberous
sclerosis,  Peutz--Jeghers  syndrome  and  with  several  types  of
cancer  in  which  the  genetic  changes  to  the  regulating  genes
of  mTOR,  such  as  TSC1-TSC2  and  LKB1,  present  diverse  types
of  mutations.42--44
During  bone  formation,  the  RUNX2  gene  is  key  for  the
differentiation  of  the  osteoblastoma,  and  for  the  prolifera-
tion  of  chondrocytes  and  endochondral  differentiation  and
hypertrophy.  Its  participation  as  the  promoter  of  tumour  in
breast  and  prostate  cancer  has  been  reported,  as  well  as  its
association  with  genes  which  control  tumour  invasion  and
metastasis,  since  it  promotes  the  expression  of  the  metal-
loproteinases  MMP2,  MMP13,  MMP14.  In  this  way,  RUNX2  has
been  deﬁned  as  a  promigratory  transcription,  pro-invasive,
and  pro-angiogenic  factor,  in  addition  to  participating  in  the
initial  events  of  tumorogenesis  and  leading  the  spread  of
bone  metastasis.43--45
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The  expression  and  activity  of  RUNX2  is  induced  directly
nd  indirectly  by  Akt.  In  vitro  experiments  made  with  cancer
ells  have  shown  that  the  activation  of  the  PI3K/Akt  intracel-
ular  communication  pathway  leads  directly  to  an  increase
n  afﬁnity  to  DNA  by  the  RUNX2  and  RUNX2-dependent
actors  of  transcription  and  that  the  mutations  affecting
kt  lead  to  a  decrease  in  the  afﬁnity  of  RUNX2,  which
ffects  the  progression  of  the  cellular  cycle.  Indirectly,
ctivation  of  the  PI3K/Akt  pathway  regulates  RUNX2  activ-
ty,  since  it  increases  its  protein  stability  either  by  acting
hrough  a  nuclear  transcription  factor  called  FoxO,  an  acti-
ator  or  a speciﬁc  gene  transcriptional  repressor  and  the
ytoplasm.46,47
utations  and  thyroid  cancer
 mutation  of  any  protein  involved  in  the  intracellular
ignalling  cascade  measured  by  a  tyrosine  type  receptor  may
etermine  that  a  normal  cell  becomes  a  cancer  cell.  In  this
ontext,  it  has  been  reported  that  around  70%  of  patients
ho  present  with  papillary  thyroid  cancer  have  at  least  one
utation  which  affects  the  ERK  activation  cascade;  the  most
requent  are  those  affecting  Ras  and  B-Raf  and,  to  a  lesser
egree,  RET/PTC.
The  prevalence  of  RET/PTC  mutations  in  thyroid  cancer  is
aried,  since  it  depends  on  the  geographic  region,  but  it  may
e  stated  that  approximately  20%  of  cases  of  thyroid  cancer
resent  these  alterations,  and  also  that  it  is  more  frequent
n  young  people  or  those  with  a  background  of  having  under-
one  radiation  treatment.  Furthermore,  the  mutations  in  a
ember  of  the  gene  family  which  code  for  the  protein  Ras
ave  been  primarily  described  in  follicular  adenoma  and  thy-
oid  carcinoma,  but  only  described  in  around  10%  of  papillary
hyroid  cancer  cases.33
In  the  case  of  B-Raf  (which  may  also  be  expressed  as
Raf)  it  has  been  observed  that  it  is  expressed  in  a  nor-
al  manner  in:  blood  forming  cells,  neurons,  testicular
ells  and  in  thyroid  follicular  cells.  Contrary  to  that  which
ccurs  with  the  mutations  in  A-Raf  and  Raf-1  which  are
xtremely  rare,  mutations  in  B-Raf  are  the  most  frequent
n  papillary  thyroid  cancer,  as  well  as  being  the  second
omatic  mutation  found  in  all  types  of  cancer  which  affect
he  human  being.  Thus,  for  example,  over  45%  of  all  types
f  cancer  which  affect  the  human  being  present  a  muta-
ion  in  B-Raf.  Close  to  90%  of  these  mutations  consist  of
 replacement  of  a  timine  for  an  adenine  in  the  exon
5  of  the  neucleotide  1799  (c.1799T>A),  which  results  in
 mutation  of  B-Raf,  where  a  valine  residual  is  replaced
y  a  glutamic  acid  residual  in  the  protein  position  600.
his  mutation  is  expressed  as  BRAFV600E  (also  expressed
s  B-Raf-V600E  or  BRAF-V600E).  It  has  been  reported  that
he  prevalence  of  this  mutation  in  papillary  thyroid  can-
er  may  vary  from  29%  to  83%,  depending  on  the  sample
tudied,  and  has  not  been  described  in  follicular  thyroid
ancer.48 Research  studies  carried  out  in  vitro  have  shown
hat  the  replacement  of  the  valine  for  a  glutamic  acid
n  600  position  adjacent  to  a  threonine  residual  in  posi-
ion  599  within  protein  B-Raf  induces  similar  behaviour
o  a  phosphorylation,  which  makes  the  tertiary  structure
f  the  protein  affected  where  the  hydrophobic  interac-
ions  break  between  segment  P  (the  activation  site  of  the
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rotein  by  phosphorylation)  and  the  kinase  activity  seg-
ent,  resulting  in  the  BRAFV600E  kinase  activity  being
60  times  higher  than  the  native  B-Raf.  This  raised  con-
tituitive  activity  of  BRAFV600E  produces  a  downstream
ctivation  of  all  effectors  of  the  signalling  cascade  effec-
ors  up  to  ERK,which  results  in  the  transformation  of
ormal  cells  into  cancer  cells,  and  their  unnecessary  pro-
iferation  of  Ras  protein,  for  activation  of  the  signalling
athway.
It  has  been  proven  that  the  presence  of  BRAFV600E
s  linked  to  genes  involved  in  the  metabolism  of  iodine,
specially  those  involved  in  the  uptake  of  iodine  by  cells
or  thyroid  hormone  synthesis.  The  presence  of  BRAFV600E
nduces  the  thyroid  cells  to  present  changes  in  several  of  the
enes  involved  in  this  process,  which  have  been  associated
ith  a  greater  aggressive  tumour  pattern.  The  presence  of
utations  in  the  BRAF  gene  has  therefore  been  correlated
ith  a  poor  response  to  standard  chemotherapy  treatment
nd  also  is  an  indication  of  poor  prognosis,  since  the  muta-
ion  in  BRAF  was  found  both  in  anaplasic  cells  and  in  poorly
ifferentiated  carcinomas,  which  means  that  the  molecular
hanges  in  B-Raf  are  produced  early  on  in  the  tumorogenesis
henomenon.48
e-arrangements  in  PAX8-PPAR in  thyroid  cancer
he  PAX8  gene  is  a  speciﬁc  thyroid  transcription  factor  which
egulates  development  and  differentiation.  Furthermore,
he  PPAR gene  is  involved  in  the  control  of  the  cellular
ycle,  apoptosis  and  carcinogenesis,49 as  well  in  adipogene-
is  and  sensitivity  to  insulin.
Together  PAX8  and  PPAR have  a  key  role  in  thyroid
ancer.  The  translocation  between  these  2  genes  pro-
uces  a  new  gene,  the  overexpression  of  the  resulting
AX8/PPAR  or  PPFP  fusion  protein  alters  the  PPAR function
f  the  downstream  inhibitor  of  the  cellular  proliferation  and
poptosis  inductor.  The  chromosomal  translocation  PAX8-
PAR was  detected  in  35%  of  follicular  thyroid  cancer
nd  anaplasic  thyroid  cancer.49 Furthermore,  in  follicular
hyroid  cancer  the  overexpression  of  PAX8/PPAR is  asso-
iated  with  the  activation  of  a  MAP  kinases  depending  on
GFß  receptors,  which  is  closely  linked  to  the  tumorogeneis
rocess.49,50
olecular  therapy  in  thyroid  cancer
hyroid  cancer,  whether  it  be  papillary  or  follicular,  which  is
ell  differentiated,  has  a  fairly  promising  clinical  behaviour
attern  since  it  may  be  treated  with  surgery,  followed
y  radiotherapy.  However,  the  tumours  which  are  undif-
erentiated  or  those  which  lose  their  capacity  to  capture
adioactive  iodine  cannot  be  surgically  removed,  and  are
herefore  tumours  of  poor  prognosis.  This  type  of  tumours
ay  be  treated  with  molecular  therapy,  where  the  intra-
ellular  signalling  chain  (RET/PTC)/Ras/Raf/MEK/ERK  is  a
requent  target  for  molecular  therapy  studies.
Molecular  therapy  is  of  great  interest  in  this  type  of
ancer  as  drugs  have  been  developed  which  inhibit  sev-
ral  of  the  components  of  the  (RET/PTC)/Ras/Raf/MEK/ERK
ignalling  pathway.  Particular  emphasis  has  been  place  on
he  (RET/PTC)/Ras/Raf  section,  as  this  segment  of  the
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ignalling  cascade  is  the  main  ERK  effector.  It  has  been
eported  that  the  ZD6474  compound,  which  is  a  RET/PTC
inase  activity,  has  been  effective  in  in  vitro  and  pre-
linical  trials  to  induce  arrest  of  the  cellular  cycle  in
uman  papillary  carcinoma,  and  this  impedes  its  growth
hen  injected  in  mice.51 The  compounds  pyrazolopyrimi-
ine  (PP1  y  PP2)  and  sunitinib  (SU12248)  have  also  been
ested  in  in  vitro,  in  vivo  and  preclinical  trials.  These
ullify  the  RET/PTC  signal  for  eliminating  the  tumori-
enic  effect  in  test  animals.  Promising  results  have  also
een  reported  in  phase  II  clinical  trials  ii in  treating
atients  who  do  not  respond  to  treatment  with  radioac-
ive  iodine  or  who  have  unresectable  tumours,  and  also
n  those  patients  who  present  with  medullary  thyroid
ancer.52--54
Furthermore,  it  has  been  reported  that  the  compounds
DC-0879  and  PLX4720  selectively  inhibit  the  kinase  activ-
ty  of  BRAFV600E  in  vitro,  which  results  in  the  tumour
ells  reducing  their  proliferation.  However,  these  have  only
roven  effective  in  preclinical  trials.  On  the  other  hand,
t  has  been  observed  that  patients  who  present  with  the
RAFV600E  mutation  may  develop  resistance  to  this  type
f  compounds,  since  they  increase  the  Raf-1  expression  by
ctivating  Ras  (generally  over  expressed)  and  thus  the  down-
tream  signalling  cascade  towards  ERK  may  continue  being
ctive.  This  event  proves  the  need  for  a  precise  genotyp-
ng  for  each  type  of  tumour,  since  it  is  necessary  to  ensure
hat  the  possible  mutations  have  been  detected  in  a  few
r  several  components  of  the  signalling  chain  components
hich  activate  ERK,  since,  although  one  component  is  nul-
iﬁed,  another  may  be  activated  and  continue  with  the
umour  proliferation  process.  That  previously  stated  also
roves  that  treatment  should  be  include  several  compounds
t  the  same  time  to  ensure  a  better  inhibitory  outcome  of
he  signalling  cascade,  and  all  the  more  so  when  tumour
esistance  to  chemotherapy  alone  has  been  demonstrated
nd  in  the  case  of  those  who  present  with  the  mutation
RAFV600E,  this  type  of  combined  treatment  is  the  most
ecommended.53,54
The  PI3K/Akt/mTOR  signalling  pathway  is  another
ppealing  molecular  target,  due  to  its  therapeutic  ben-
ﬁt  reported  for  different  malignant  tumours.  The
I3K/Akt/mTOR  pathway  regulates  critical  cellular  pro-
esses  such  as  proliferation,  apoptosis,  the  cellular  cycle,
etabolism  and  angiogenesis,  whilst  several  preclinical  and
linical  studies  support  that  the  pharmacological  inhibi-
ion  of  PI3K/Akt/mTOR  represents  a  well  tolerated  and
uccessful  strategy  in  malignant  tumour  treatment,  such
s  prostate,  breast,  colon,  ovarian,  lung  and  melanoma
ancer.55 Apparently,  the  reduction  in  the  activity  of
I3K/Akt/mTOR  is  related  to  the  induction  of  tumour
adiosensibility  effects,56 which  are  pro-apoptotic  effects
n  tumour  cells  related  to  lower  autophagia,  and  to
he  loss  conservation  in  cancer  cells.57 Regarding  follic-
lar  type  thyroid  cancer,  advanced  or  non  differentiated
naplasia,  resistant  to  radioactive  iodine  and  therefore
ith  a  poor  prognosis,  for  its  response  to  convention
reatment,  several  pre-clinical  and  clinical  studies  show
hat  inhibition  of  PI3K/Akt/mTOR  pathway  may  be  a
romising  strategic  target,  whether  with  monotherapy
r  combined  therapy,  in  this  type  of  advanced  thyroid
ancer.58
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Conclusions
Major  progress  has  been  made  during  the  last  30  years  in  the
ﬁeld  of  molecular  biology  aimed  at  discerning  the  mech-
anisms  involved  in  the  process  of  tumour  transformation,
primarily  in  studies  intended  to  understand  the  intracellular
systems  which  involve  Ras/Raf/MEK/ERK  kinase  cascades.
This  signalling  cascade  controls  cellular  proliferation  in  nor-
mal  cells  and  cancer  cells.  Moreover,  they  are  important
pathways  in  the  development  of  resistance  to  the  drugs  used
in  chemotherapy.
Current  studies  have  proven  that  the  Ras/Raf/MEK/ERK
signalling  cascade  induces  malignant  proliferation,  since  it
stimulates  cellular  growth  and  simultaneously  inhibits  apo-
ptosis  (programmed  cell  death).  Furthermore,  the  discovery
that  mutations  in  the  BRAF  gene  may  alone  lead  to  cel-
lular  transformation  and  proliferation  in  several  types  of
cancer,  mainly  thyroid  cancer,  has  highlighted  the  need
for  further  studies  to  be  conducted  on  the  control  mech-
anisms  of  this  type  of  genes  and  their  products.  This  would
include  the  development  of  effective  chemical  agents  to
nullify  this  type  of  protein  and  thus  control  the  growth  and
development  of  cancer  cells.59 That  expressed  above  also
underlines  the  need  for  greater  study  of  tumour  genotyp-
ing,  due  to  their  signiﬁcant  in  molecular  therapy  usage.
The  description  of  mutations  in  BRAF  may  predict  the  sen-
sitivity  of  B-Raf  to  several  anti-cancer  agents  and  inhibit
the  downstream  to  ERK  and  therefore  inhibit  growth  and
development  of  tumours.  Genotyping  of  the  tumour  is  also
useful  for  predicting  clinical  behaviour  of  the  tumour,  to
ensure  correct  administration  of  drugs  and  avoid  confusion
regarding  the  type  of  drugs  to  be  applied  when  there  is
the  possibility  of  resistance  from  tumours.  Worldwide  clini-
cal  research  indicates  that  molecular  therapy  aimed  against
mutations  in  the  BRAF  may  be  promising.  However,  there  is
still  much  research  to  be  carried  out  since  each  anti-cancer
compound  aimed  at  any  component  of  the  Ras/Raf/MEK/ERK
chain  must  prove  its  clinical  usage  in  patients  with  can-
cer.  However,  the  application  at  the  same  time  of  several
types  of  drugs  for  inhibiting  the  Ras/Raf/MEK/ERK  chain
and  the  combination  with  standard  chemotherapy  appears
to  be  the  most  effective  plan  for  thyroid  cancer  treat-
ment.  Notwithstanding,  the  risk  of  developing  resistance  is
always  latent,  and  the  development  of  further  and  improved
products  for  cancer  control  treatment  is  an  absolute  pri-
ority,  especially  if  the  development  of  these  drugs  led  to
more  generalised  usage  and  their  availability  in  hospitals
became  standard,  thus  promoting  wellbeing  for  the  cancer
patient.
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